KRAS and neoplasm: As in the wild-type KRAS exon 2 population, treatment with panitumumab plus BSC improved OS vs BSC alone for patients with wild-type RAS tumours (median (95% CI): 10.0 (8.7–11.6) months vs 6.9 (5.2–7.9) months; HR=0.70; 95% CI=0.53–0.93; P=0.0135; Figure 2B, Table 2).